These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17952387)

  • 1. Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children.
    Rodriguez CA; Koch S; Goodenow M; Sleasman JW
    Immunol Res; 2008; 40(3):271-86. PubMed ID: 17952387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy.
    Ghaffari G; Passalacqua DJ; Caicedo JL; Goodenow MM; Sleasman JW
    Pediatrics; 2004 Nov; 114(5):e604-11. PubMed ID: 15492356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness.
    Ometto L; De Forni D; Patiri F; Trouplin V; Mammano F; Giacomet V; Giaquinto C; Douek D; Koup R; De Rossi A
    AIDS; 2002 Apr; 16(6):839-49. PubMed ID: 11919485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.
    Plana M; Martínez C; García F; Maleno MJ; Barceló JJ; García A; Lejeune M; Vidal C; Cruceta A; Miró JM; Pumarola T; Gallart T; Gatell JM
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):429-34. PubMed ID: 11981357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume.
    Vigano A; Vella S; Saresella M; Vanzulli A; Bricalli D; Di Fabio S; Ferrante P; Andreotti M; Pirillo M; Dally LG; Clerici M; Principi N
    AIDS; 2000 Feb; 14(3):251-61. PubMed ID: 10716501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control.
    Sufka SA; Ferrari G; Gryszowka VE; Wrin T; Fiscus SA; Tomaras GD; Staats HF; Patel DD; Sempowski GD; Hellmann NS; Weinhold KJ; Hicks CB
    J Infect Dis; 2003 Apr; 187(7):1027-37. PubMed ID: 12660916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy.
    Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M
    J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
    Jankelevich S; Mueller BU; Mackall CL; Smith S; Zwerski S; Wood LV; Zeichner SL; Serchuck L; Steinberg SM; Nelson RP; Sleasman JW; Nguyen BY; Pizzo PA; Yarchoan R
    J Infect Dis; 2001 Apr; 183(7):1116-20. PubMed ID: 11237839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.
    Staszewski S; Miller V; Sabin C; Schlecht C; Gute P; Stamm S; Leder T; Berger A; Weidemann E; Hill A; Phillips A
    AIDS; 1999 May; 13(8):951-6. PubMed ID: 10371176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children.
    Resino S; Galán I; Pérez A; Ramos JT; Bellón JM; Fontelos PM; de José MI; Gutiérrez MD; Cabrero E; Muñoz-Fernández MA
    AIDS Res Hum Retroviruses; 2005 May; 21(5):398-406. PubMed ID: 15929702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy.
    Resino S; Seoane E; Pérez A; Ruiz-Mateos E; Leal M; Muñoz-Fernández MA
    BMC Infect Dis; 2006 Jul; 6():112. PubMed ID: 16839416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages.
    Sleasman JW; Nelson RP; Goodenow MM; Wilfret D; Hutson A; Baseler M; Zuckerman J; Pizzo PA; Mueller BU
    J Pediatr; 1999 May; 134(5):597-606. PubMed ID: 10228296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.
    De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M
    Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. Royal Free Centre for HIV Medicine.
    Youle M; Janossy G; Turnbull W; Tilling R; Loveday C; Mocroft A; Tyrer M; Madge S; Wilson D; Dykhoff A; Johnson M; Phillips AN
    AIDS; 2000 Aug; 14(12):1717-20. PubMed ID: 10985307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
    Rizzardi GP; Tambussi G; Bart PA; Chapuis AG; Lazzarin A; Pantaleo G
    AIDS; 2000 Oct; 14(15):2257-63. PubMed ID: 11089613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.